Latest News and Press Releases
Want to stay updated on the latest news?
-
Below are the expected dates for Exiqon A/S’ annual general meeting and financial reporting in 2014. Financial calendar Announcement of full-year results 2013: 10 February...
-
Nedenstående viser forventede datoer for Exiqon A/S’ afholdelse af ordinær generalforsamling samt regnskabsrapportering i 2014. Finanskalender Offentliggørelse af...
-
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) offentliggjorde i dag resultatet for de første ni måneder af 2013: Finansielle højdepunkter (mio. kr.) Q3 2013 Q3...
-
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for the first nine month of 2013: In summary (DKK million) Q3 2013 Q3 2012 Q3 YTD...
-
Exiqon A/S (NASDAQ OMX: EXQ), en førende leverandør af højt specialiserede produkter til genanalyse, offentliggjorde i dag lanceringen af yderligere produkter i LNA™ longRNA GapmeR produkt linjen...
-
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced an extension to the LNA™ longRNA GapmeR product line with the launch of a novel...
-
Bestyrelsen for Exiqon A/S besluttede den 16. august 2013 at udstede 553.110 stk. warrants til direktionen i Exiqon A/S – ikke 563.110 stk. warrants som anført i meddelelse nr. 7 af 16. august 2013,...
-
On 16 August 2013 the supervisory board of Exiqon A/S resolved to issue 553,110 warrants to the executive board of Exiqon A/S – not 563,110 warrants as was stated in announcement no. 7 of 16 August...
-
The supervisory board of Exiqon A/S has on this 16 August 2013 resolved to issue 563,110 warrants to the executive board of Exiqon A/S. All warrants have been issued in accordance with the...
-
Bestyrelsen for Exiqon A/S har i dag den 16. august 2013 besluttet at udstede 563.110 stk. warrants til direktionen i Exiqon A/S. Samtlige warrants er udstedt i henhold til bemyndigelse i...